Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 075 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride maintains intracellular tonicity and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and may decrease protein and nitrogen loss. Sodium chloride maintains extracellular fluid volume and electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion; rate determined by fluid and electrolyte needs; typical adult rate: 100-200 mL/hour (contains 10 g dextrose, 9 mEq sodium, 0.075 g potassium chloride per 100 mL); maximum potassium infusion rate: 10 mEq/hour (13.3 mL/hour of this solution) unless critical hypokalemia.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium has no true elimination half-life due to tight homeostatic regulation; the terminal half-life of potassium tracer is approximately 12-14 hours in healthy individuals. Clinically, redistribution half-life is ~1 hour. Effect persists as long as infusion continues, with transient changes after cessation.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Fecal elimination accounts for ~10% under normal conditions. Dextrose and sodium chloride are fully metabolized or excreted renally.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."